ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / FULC / news
LYEL (30) BIOA (31) RCKT (28) VOGX (45) ⌘ Pro Terminal →

Why FULC Stock slipped -1.62% Today — RQD Quant Desk Flash

$3.65 -1.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.63

Fulcrum Therapeutics Inc. (FULC) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $283.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FULC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FULC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Fulcrum Therapeutics Inc. (NASDAQ: FULC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.65 (-1.62% 1D, market cap $283.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, FULC ranks #715 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FULC compare to LYEL and BIOA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FULC carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LYEL (Lyell Immunopharma Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $270.5M) and BIOA (BioAge Labs Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $269.4M). Among the 5-stock peer group, FULC leads on earnings multiple (N/A) while FULC leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FULC?
▼

Per FULC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680581), Fulcrum Therapeutics Inc. generated $237.4M in revenue (+287.1% YoY), -$74.9M in net income, and -$60.4M in free cash flow against $366.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.63 (-0.48%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (7)Whales (6)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.8% Base Target
$17 Bull$3 Base$3 Bear
📬 FREE FULC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FULC)Realized 20D OHLCV Swing Band: ±3.8%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY FULC SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$3.68+1.1% Next Q
Q2 (-2Q)
37
Grade E$3.72-0.5% Next Q
Q3 (-1Q)
35
Grade E$3.70-1.4% Next Q
Current
32
Grade E$3.65-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FULC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FULC currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.76) and Max Pain ($3.83) forces dealer call-delta covering toward $16.53.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FULC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FULC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why FULC Stock slipped -1.62% Today — RQD Quant Desk Flash

Fulcrum Therapeutics Inc. (FULC) slipped -1.62% to $3.65, trading at 6% of its 52-week range ($2.83 – $15.74). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 6% of its 52-week range ($2.83 – $15.74) with RSI-14 at 48.7 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±3.8% around $3.65 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live FULC Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FULC)

  • ✓Walkthrough of FULC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
FULC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -48.01%⚡ TESTING RESISTANCE
2026-11-03O $3.77H $3.77L $3.65C $3.65VOL 933.2K
RES: $3.79SUP: $3.64SMA50: $3.76SMA200: $5.80
$9.25$7.51$5.77$4.03$2.29RES $3.79SUP $3.64$3.652026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FULC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FULC Butterfly Map → + Track FULC →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +287.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on FULC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FULC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FULC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FULC)

Health Care Rank #715 of 1015 ⚔️ LYEL vs FULC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FULC vs. LYEL, BIOA, RCKT, VOGX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Fulcrum Therapeutics Inc. (FULC) ranks #715 by composite RQD confidence (32/100, grade E) and #522 by equity capitalization ($283.4M). Within this direct 5-issuer industry benchmark cohort, FULC leads on earnings valuation at N/A trailing P/E, while FULC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with FULC at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
FULC ACTIVE
Fulcrum Therapeutics Inc.
E 32/100 — — -35.0% -1.62% $283.4M Benchmark Subject
LYEL
Lyell Immunopharma Inc.
E 30/100 — — -35.0% -1.45% $270.5M /lyel-vs-fulc →
BIOA
BioAge Labs Inc.
E 31/100 — — -35.0% -1.19% $269.4M /bioa-vs-fulc →
RCKT
Rocket Pharmaceuticals Inc.
E 28/100 — — -35.0% +1.23% $267.9M /rckt-vs-fulc →
VOGX
Vogenx Inc
D 45/100 — — — +2.42% $300.8M /vogx-vs-fulc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001680581 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fulcrum Therapeutics Inc. (FULC) reported GAAP revenue of $237.4M (+287.1% vs. FY2024 revenue of $61.3M , and -23.4% cumulative change since FY2023) , GAAP net income of -$74.9M, operating cash flow of -$60.1M, and free cash flow of -$60.4M (-2319.0% YoY). On the balance sheet, FULC closed FY2025 with $366.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $237.4M -$74.9M -$60.1M -$60.4M $366.3M —
FY2024 (FY) 2024-12-31 $61.3M -$9.7M -$2.2M -$2.5M $260.7M —
FY2023 (FY) 2023-12-31 $309.9M -$97.3M -$91.0M -$91.0M — —

3. FULC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FULC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Fulcrum Therapeutics Inc. (NASDAQ: FULC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.65 (-1.62% 1D, market cap $283.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, FULC ranks #715 in composite RQD confidence.

How does FULC compare to LYEL and BIOA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FULC carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LYEL (Lyell Immunopharma Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $270.5M) and BIOA (BioAge Labs Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $269.4M). Among the 5-stock peer group, FULC leads on earnings multiple (N/A) while FULC leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FULC?

Per FULC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680581), Fulcrum Therapeutics Inc. generated $237.4M in revenue (+287.1% YoY), -$74.9M in net income, and -$60.4M in free cash flow against $366.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FULC trading relative to its 50-day, 200-day, and 52-week technical levels?

FULC last traded at $3.65 (-1.62% on volume of 1,213,827 shares), positioning the stock -2.93% below its 50-day simple moving average ($3.76) and -37.07% below its 200-day simple moving average ($5.80). Across its 52-week range of $2.83 to $15.74, FULC sits at the 6.4% percentile with a 14-day RSI of 48.7 (NEUTRAL RANGE) and an implied next-earnings move of ±3.8% ($3.51 to $3.79).

Direct Sub-Reports: FULC RQD Cockpit FULC 12M Forecast FULC Earnings & Move FULC Dividends & DRIP FULC Insiders & 13F FULC Whale Options FULC Profit Sankey FULC News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

FULC — Fulcrum Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Fulcrum Therapeutics Inc. (FULC) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.65 (-1.62% 1D, market capitalization $283.4M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -20.97%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Fulcrum Therapeutics Inc. (FULC) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..3B. The FY 2025 and FY 2024 financials report revenue of — in each period.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Fulcrum Therapeutics Inc. (FULC) reported $237.4M in annual revenue (up from $61.3M in FY2024, +287.1% YoY) and -$74.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($309.9M revenue, -$97.3M net income) through FY2025, FULC scaled operating cash flow to -$60.1M and free cash flow to -$60.4M, backed by $366.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -20.97% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $2.83 – $15.74 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), FULC carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can FULC sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $237.4M and free cash flow of -$60.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is FULC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

FULC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Fulcrum Therapeutics Inc. (FULC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FULC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FULC Bull vs. Bear Conversation Board — What's Your Call at $3.65?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FULC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on FULC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $4.60 (+24.0%)
📌 Pinned Debate

Reported cash of $197.5M in FY 2025, up from $58.2M in FY 2024, provides a liquidity cushion against current losses.

Here is why I am bullish on FULC here at $3.71: Reported cash of $197.5M in FY 2025, up from $58.2M in FY 2024, provides a liquidity cushion against current losses.. Compare FULC's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $3.52 are getting bought.

CapAlloc_Nerd 🐂 BULL

@TapeReader_Pro Agree on the RQD 32/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.71 and keeping dry powder in case we test $3.45.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $2.78 (-25.1%)
Spot @ $3.71

Negative ROIC of -35%, FCF yield of -20.97%, and zero reported revenue in every period show no current cash-generation engine.

Careful chasing FULC at $3.71. Negative ROIC of -35%, FCF yield of -20.97%, and zero reported revenue in every period show no current cash-generation engine.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $2.78 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%